HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup
Archive

All News

Every briefing, headline, and filing we've published, newest first.

The WeekPharmaVoice ↗
The red-hot market has plenty of room for additional therapies from big-name players and clinical-stage compan…
Jun 29, 2026
The WeekBioPharma Dive ↗
The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure …
Jun 29, 2026
The WeekFiercePharma ↗
As Amgen prepares to defend Tavneos' market approval in the U.S., the company has received a bad omen overseas…
Jun 29, 2026
AstraZeneca unveils phase 3 bone disease data behind $5B forecast for Strensiq successor
The WeekFierceBiotech ↗
AstraZeneca has shared the data behind previously disclosed phase 3 rare disease wins, fleshing out the case f…
Jun 29, 2026
Week’s End: 340B Overhaul Bill and Next FDA Chief in Play
The WeekBriefing
STAT News flagged two developments: a congressional bill to revamp the 340B drug discount program and talk of …
Jun 29, 2026
The WeekDrug Channels ↗
Happy 250th birthday, America! Before you launch your semiquincentennial festivities, Drug Channels offers som…
Jun 29, 2026
STAT+: Moderna co-founder Kenneth Chien on the future of mRNA - and Moderna
The WeekSTAT News ↗
In a Q&A, Kenneth Chien, no longer with Moderna, predicts the company's mRNA cancer vaccine will be transforma…
Jun 29, 2026
The WeekFiercePharma ↗
Held just after the prestigious Cannes Film Festival in southern France, the Cannes Lions Festival of Creativi…
Jun 28, 2026
Biogen ends Apellis research programs, cuts 'small number' of roles after $5.6B buyout
The WeekFierceBiotech ↗
Biogen isn't wasting any time integrating its multibillion-dollar purchase of Apellis, revealing plans to part…
Jun 28, 2026
Embryo Editing Progress Rekindles Ethics Fight
The WeekBriefing
STAT reports that new technical advances in embryo genome editing are again stirring public and policy debate …
Jun 28, 2026
Opinion: Supreme Court ruling on Roundup points to a confusing difference between the law and science
The WeekSTAT News ↗
The Supreme Court's ruling on Roundup shows science and law use the same word - causation - while asking diffe…
Jun 27, 2026
The WeekFiercePharma ↗
The agency spotted seven observations at Dr. Reddy's Bachupally, Hyderabad, biologics plant following a mid-Ju…
Jun 27, 2026
Fierce Biotech Layoff Tracker 2026: Biogen sheds Apellis R&D roles; ADC Tx slims workforce
The WeekFierceBiotech ↗
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial tea…
Jun 27, 2026
EU Opens Antitrust Proceedings Against Sanofi Over Efluelda Marketing
The WeekBriefing
The European Commission has launched formal antitrust proceedings into Sanofi’s flu vaccine marketing. The cas…
Jun 27, 2026
BIO 2026: AI, federal policy impacts, and general vibes
The WeekSTAT News ↗
What were the vibes like at BIO 2026? STAT reporters take you inside the annual industry conference on the lat…
Jun 26, 2026
The WeekAJMC ↗
Health Equity & Access Weekly Roundup: June 26, 2026…
Jun 26, 2026
The WeekBioPharma Dive ↗
Replimune's application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicine…
Jun 26, 2026
The WeekBioPharma Dive ↗
Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb …
Jun 26, 2026
The WeekBioPharma Dive ↗
Blair Jackson says the next 12 months may be the most important in Alkermes' history, as the brain drugmaker r…
Jun 26, 2026
The WeekPharmaVoice ↗
AI hasn't always been what it was cracked up to be in pharma. Here's where execs say the technology hasn't liv…
Jun 26, 2026
The WeekFiercePharma ↗
BeOne Medicines has extended its relationship with Blood Cancer United, committing $5 million over three years…
Jun 26, 2026
How iBio aims to stand out in obesity by targeting 'both sides of the equation' for antibody discovery
The WeekFierceBiotech ↗
Upon finally reaching the clinic, iBio feels vindicated about the artificial intelligence-powered discovery pl…
Jun 26, 2026
Otsuka’s centanafadine clears Phase 3b hurdle ahead of FDA ADHD decision
The WeekBriefing
Otsuka’s ADHD drug candidate met its Phase 3b endpoint in adults with comorbid anxiety, adding key data weeks …
Jun 26, 2026
The WeekDrug Channels ↗
Today's guest post comes from Geoffrey Chaiken and Matthew Chaiken, Co-founders of BlinkRx. Geoffrey and Matth…
Jun 26, 2026
← Newer Page 5 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.